ICR hails ‘momentous’ recommendation of olaparib for breast and prostate cancer 05 Apr 2023 The Institute of Cancer Research, London, has hailed the ‘life-changing’ decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer. Find out more Show/Hide
Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer 02 Dec 2019 A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows. Find out more Show/Hide
ASCO 2019: Breast cancer drug effective in 80 per cent of men with BRCA-mutant prostate cancer 05 Jun 2019 A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Find out more Show/Hide